Coronavirus information for participants
The onsite course and conference programme at EMBL has been paused until the end of June 2020.
We aim to continue offering our advanced training for the scientific community however we safely can. While some events have been cancelled, many have been rescheduled for a later date and others will be delivered as virtual events.
Registration is open for onsite courses and conferences starting after 1 July and for the virtual events. All registration fees for any events which don’t take place due to the COVID-19 disruption are fully refundable.
More information for participants of events at EMBL Heidelberg can be found here.
This conference will provide an opportunity to learn about and keep up to date with the rapidly progressing area of cancer genomics. It will cover presentations from cancer genome projects, the areas of cancer functional genomics, systems biology, cancer immunogenomics and epigenomics, cancer mouse models and the translation and clinical impact of scientific results obtained. The meeting will bring together leading scientists from across these areas for a unique opportunity to interact and stimulate further integration of these efforts.
European cancer genomics research is particularly strong in the Heidelberg area, with three International Cancer Genome Consortium (www.icgc.org) projects being currently pursued with significant participation from Heidelberg institutions, including EMBL. As in our 2017 meeting, a large number of renowned speakers will be invited, with a strong representation of overseas speakers. The atmosphere at the conference will make this an exceptional event with cutting edge science, extensive scientific discussions and ample possibilities for meetings between and after sessions to facilitate in-depth discussions and new collaborations.
Cancer genetics and mutation
Drivers of cancer and genome-wide functional screens
Cancer genome and epigenome
Cancer and microenvironment: immunogenomics and single cells
Cancer genome medicine